Figure 1. Changes in alanine aminotransferase (ALT) level of the anti-HBc group during direct-acting antivirals (DAAs) treatment.
| Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc |
| Journal website http://www.gastrores.org |
Original Article
Volume 11, Number 2, April 2018, pages 124-129
Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
Figures
Tables
| HBsAg group (N = 11) | Anti-HBc group (N = 53) | P-value | |||
|---|---|---|---|---|---|
| M ± SD | N (%) | M ± SD | N (%) | ||
| P-values were analyzed with Pearson’s Chi-square test#, Fisher’s exact test∧, and t-test*. HCC: hepatocellular carcinoma; M: mean; N: number of patients; SD: standard derivation. | |||||
| Age | 63.18 ± 9.35 | 65.66 ± 10.53 | 0.446* | ||
| Gender (male) | 5 (45.5%) | 24 (45.3%) | 0.992# | ||
| Treatment experience | 7 (63.9%) | 32 (60.4%) | 0.840∧ | ||
| Cirrhosis | 5 (45.5%) | 16 (30.2%) | 0.326# | ||
| HCC | 3 (27.3%) | 18 (33.9%) | 1.000∧ | ||
| HBsAg group (N = 11) | Anti-HBc group (N = 53) | P-value | |||
|---|---|---|---|---|---|
| M ± SD | N (%) | M ± SD | N (%) | ||
| P-values were analyzed with Fisher’s exact test∧ and t-test*. ALT: alanine aminotransferase; DAAs: direct-acting antivirals; ETVR: End-of-treatment virologic response; M: mean; N: number of patients; SD: standard derivation; SVR: sustained virologic response; VR: virologic response. | |||||
| HCV genotype | 0.310∧ | ||||
| 1a | 0 | 4 (7.5%) | |||
| 1b | 10 (90.9%) | 48 (90.6%) | |||
| 2 | 1 (9.1%) | 1 (1.9%) | |||
| Mean HCV RNA (106 IU/mL) | 1.85 ± 2.67 | 2.21 ± 2.55 | 0.688* | ||
| Mean ALT (U/L) | 67.55 ± 44.08 | 108.45 ± 136.50 | 0.068* | ||
| DAAs efficacy | |||||
| VR4 | 11 (100%) | 51 (96.2%) | 1.000∧ | ||
| ETVR | 11 (100%) | 53 (100%) | 1.000∧ | ||
| SVR12 | 11 (100%) | 53 (100%) | 1.000∧ | ||